|
Sep 24
|
Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc
|
|
Sep 23
|
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
|
|
Sep 19
|
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc
|
|
Sep 16
|
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
|
|
Jul 25
|
Passage Bio targets FDA to greenlight ALS gene therapy trial
|
|
May 14
|
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
|
|
Apr 22
|
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
|
|
Mar 7
|
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
|
|
Mar 5
|
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
|
|
Mar 4
|
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
|
|
Dec 20
|
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
|
|
May 4
|
Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award
|